옵션 체인은 다양한 행사가격과 만기일에 대한 Blue Bird의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Blue Bird에 대한 시장 심리를 평가합니다..

Blue Bird (NASDAQ:BLBD) 주식, 옵션 체인

Blue Bird

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

BLBD

USFD

목요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다:

목요일 주목해야 할 주식: 일라이 릴리, US 푸즈, 블루 버드 그리고 종목

Equities

Government

Regulations

Movers

Media

General

STLA

미국 바이든 행정부는 제너럴 모터스(NYSE:GM)와 크라이슬러(Chrysler)의 모회사인 스텔란티스(NYSE:STLA)에 현재 시설을 전기 자동차 및 관련 부품 제조 허브로 전환하기 위해 약 11억 달러의 자금을 지원할 계획이다.

바이든 행정부, 제너럴 모터스, 스텔란티스 등의 EV 제조 시설에 17억 달러 투자

Tech

LCID

RIVN

TSLA

전기 자동차(EV) 주식이 좋은 한 해를 보내고 있는 것은 아니지만, 저공해 스쿨버스를 만드는 한 회사는 가치 평가를 두 배 이상 높여 자동차 부문의 거물급 기업들을 곤경에 빠뜨렸다. 어떤 일이 (What Happened): Benzinga Pro의 데이터에 따르면 1927년부터 여러 세대의 학생들이 사용하는 상징적인 노란색 미국 스쿨 버스를 만드는 블루 버드(NASDAQ:BLBD)의 주가는 올해 거의 117% 급등하여 시가총액 18억 5천만 달러에 도달했다.

미국의 상징적인 스쿨 버스 제조사가 117%의 주가 급등으로 EV와 자동차 대기업들을 압도

Blue Bird Corp

Shares of MongoDB Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) tanked in early trading on Thursday, despite the company reporting <a href="https://www.benzinga.com/news/earnings/25/03/44153596/mongodb-stock-plunges-after-q4-results-fy26-guidance-below-estimates">upbeat fourth-quarter results</a>.
The results came in amid a<a href="https://www.benzinga.com/earnings"> positive earnings season</a>. Here are some key analyst takeaways.
Wedbush On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">Analyst Daniel Ives</a> reiterated an Outperform, while cutting the price target from $360 to $300.
MongoDB's total revenues grew 20% year-on-year to $548.4 million, beating Street expectations of $520.6 million, Ives said. Subscription revenue of $531.0 million also came in above consensus of $504.9 million, "as MDB looks to generate stable demand across industries for its next-gen solutions," he added.
NRR (net recurring revenues) stood at 118%, decelerating from 120% in the previous quarter, "due to a smaller contribution from existing customers," the analyst stated. "MongoDB provided relatively weak guidance across the board for FY26 as the company sees a more gradual impact from its AI solutions into FY26," he further wrote.
RBC Capital Markets On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846fffaee7bf6000154d142/rishi-jaluria">Analyst Rishi Jaluria</a> maintained an Outperform rating, while slashing the price target from $400 to $320.
MongoDB closed fiscal 2025 "on a solid note," with non-GAAP earnings of $1.28 per share beating consensus of 66 cents per share, Jaluria said. Although total revenues came in higher than consensus, growth decelerated by 2 points to 20% year-on-year, he added.
The company achieved strong profitability, with operating margins beating consensus by around 900 basis points, the analyst stated. Management's fiscal 2026 guidance was disappointing, being impacted by expectations of "a high single-digit decline in non-Atlas subscription revenue," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Rosenblatt Securities On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60081c88879cba00010420fb/blair-abernethy">Analyst Blair Abernethy</a> reaffirmed a Buy rating, while reducing the price target from $350 to $305.
MongoDB's subscription revenues grew by 19% year-on-year to $531 million, beating consensus by 6%, Abernethy said. The beat was driven by "greater than expected non-Atlas multi-year contract signings of ~$10m," he added.
While the company expects Atlas consumption growth to remain stable in fiscal 2026, its weaker revenue guidance for the year is impacted "largely by a $50m non-Atlas multi-year license headwind," the analyst stated. "Mongo continues to see a significant longer-term AI opportunity for its highly scalable, flexible document model that handles all data types," he further wrote.
Needham On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/601a8839a6fe6f00010c6966/mike-cikos">Analyst Mike Cikos</a> maintained a Buy rating, while slashing the price target from $415 to $270.
MongoDB guided to revenue growth of 16%-17% in the fiscal first quarter to a range of $524.0 million to $529.0 million and 12%-14% growth in fiscal 2026 to $2.240 billion to $2.280 billion, Cikos said. The full-year revenue guidance came well below Street expectations of $2.328 billion, he added.
The company expects non-Atlas subscription revenue to decline by a high-single-digit percentage, the analyst wrote. "All eyes are set squarely on Atlas (71% of Revenue) to drive revenue outperformance," with consumption growth stabilizing and the company poised to benefit from "a stronger cohort of acquired workloads in FY25 versus FY24," he further wrote.
Piper Sandler On MongoDB
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beeab/brent-bracelin">Analyst Brent Bracelin</a> maintained an Overweight rating, while cutting the price target from $425 to $280.
MongoDB total revenues grew 19.7% year-on-year to $548 million, "with Atlas upside contributing to a $31M beat to the midpoint guide," Bracelin said. Atlas grew by a healthy 24% year-on-year during the fiscal fourth quarter, although this marked a deceleration from the 26% reported in the previous quarter, he added.
Management indicated that Atlas consumption trends are stabilizing, the analyst stated. Bracelin said, however, that the company's growth outlook came in below 14% for second straight year.
MDB Price Action: Shares of MongoDB had declined by 21.61% to $207.06&nbsp;at the time of publication on Thursday.
Read More: &nbsp;<a href="https://www.benzinga.com/general/market-summary/25/03/44160046/marvell-surpasses-ai-chip-sales-target-aims-higher-for-2026-but-stock-plunges-due-to-muted-guidance">&nbsp;Goldman Sachs Cuts Earnings Growth Outlook, Sees Investors Move From &#8216;Excitement&#8217; To &#8216;Boredom&#8217;</a>
Photo: Shutterstock

Analyst Color

MongoDB's Solid Q4 Overshadowed By Weak FY26 Guidance, Expects Non-Atlas Headwinds

JP Morgan analyst Reginald Smith maintains CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Neutral and lowers the price target from $16 to $15.

Price Target

Analyst Ratings

CMPO

JP Morgan Maintains Neutral on CompoSecure, Lowers Price Target to $15

Susquehanna analyst Joseph Stauff upgrades Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) from Negative to Neutral and maintains the price target from $30 to $30.

Upgrades

Susquehanna Upgrades Caesars Entertainment to Neutral, Maintains Price Target to $30

JP Morgan analyst Rachel Vatnsdal maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $380 to $390.

JP Morgan Maintains Neutral on Waters, Raises Price Target to $390

On Wednesday, a federal court issued a nationwide preliminary injunction against the National Institutes of Health (NIH) following its abrupt decision to slash and cap indirect cost rates on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">biomedical research grants</a>.
The ruling prevents implementing the policy change, which would affect billions of dollars in funding and disrupt ongoing <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43618745/us-states-sue-national-institutes-of-health-over-4-billion-annual-cut-in-biomedical-research-grant-budget" rel="noreferrer noopener">research and clinical trials</a>.
The controversy began when NIH released a Supplemental Guidance on February 7, 2025, modifying indirect cost rates in grant awards.
NIH said it would now&nbsp;<a target="_blank" href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-068.html" rel="noreferrer noopener">apply</a> a standard indirect cost rate of 15% to all new and existing grants, replacing the previous practice of negotiating separate rates for each grant.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44149348/apellis-lead-drug-pegcetacoplan-represents-differentiated-asset-jp-morgan-analyst" rel="noreferrer noopener">Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst</a>
Historically, NIH's average indirect cost rate has been around 27%–28%, with some institutions charging over 50% or even 60%.
Critics argued that the policy, issued without public notice or stakeholder input, threatened the viability of research institutions nationwide.
Three separate lawsuits were filed in response, representing 22 state attorneys general, multiple medical associations, and leading universities. Thomson Reuters published a copy of the <a href="https://fingfx.thomsonreuters.com/gfx/legaldocs/zgpojbqxnvd/03052025nih_ruling.pdf" target="_blank" rel="noreferrer noopener">lawsuit</a> online.
Plaintiffs contended that NIH's unilateral action violated federal regulations, exceeded statutory authority, and failed to comply with the Administrative Procedure Act. They also cited the potential harm to life-saving clinical trials and medical advancements.
NIH has a $48 billion budget and 27 institutes that fund critical research on diseases like&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42222191/donald-trump-nominates-pandemic-critic-jay-bhattacharya-tapped-to-reshape-national-institutes-of-health-that-oversees-budget-of-48-billion" rel="noreferrer noopener">cancer and diabetes</a>.
In 2023, NIH awarded over $35 billion in research funding across nearly 50,000 grants. Of this, $26 billion went directly to research, while $9 billion covered indirect costs.
In granting the injunction, the court determined that NIH's policy change disregarded existing laws, risked substantial harm to the nation's research infrastructure, and failed to follow proper procedures.
The decision maintains the current funding structure until the legal challenges are resolved.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44161401/rio-tintos-1-8-billion-iron-ore-expansion-ramps-up-in-australia-details" target="_blank" rel="noreferrer noopener">Rio Tinto's $1.8 Billion Iron Ore Expansion Ramps Up In Australia: Details</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Legal

FHLC

FTXH

HTEC

Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations

WIIM

AMPY

Amplify Energy shares are trading lower after the company reported worse-than-expected Q4 financial results.

JP Morgan analyst Lisa Gill maintains Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) with a Overweight and raises the price target from $40 to $41.

OPCH

JP Morgan Maintains Overweight on Option Care Health, Raises Price Target to $41

Stifel analyst Thomas Stephan maintains Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) with a Buy and lowers the price target from $5 to $4.

SGHT

Stifel Maintains Buy on Sight Sciences, Lowers Price Target to $4

NINE

Nine Energy Service shares are trading higher after the company reported better-than-expected Q4 financial results.

CELZ

Creative Medical Technology Holdings shares are trading lower after the company announced agreements for exercise of warrants.

JP Morgan analyst David Karnovsky maintains Liberty Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>) with a Overweight and raises the price target from $96 to $105.

FWONK

JP Morgan Maintains Overweight on Liberty Media, Raises Price Target to $105

Stifel analyst Tore Svanberg maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $130 to $115.

MRVL

Stifel Maintains Buy on Marvell Tech, Lowers Price Target to $115

President Donald Trump's address to a joint session of Congress <a href="https://www.benzinga.com/media/25/03/44102399/heres-how-to-watch-donald-trumps-address-to-congress-time-date-and-what-to-expect">on Tuesday night</a> drew a large audience, but viewership numbers are significantly down from his previous presidential speeches.
What Happened: On Tuesday, Trump spoke for over one hour and 40 minutes. Among the <a href="https://www.benzinga.com/markets/equities/25/03/44133368/trumps-congressional-address-taps-elon-musk-for-government-overhaul-revives-drill-baby-drill-for-energy-boom">various topics he addressed</a> were tariffs, inflation, eggs, Elon Musk, the Department of Government Efficiency, international relations, oil drilling, taxation and the CHIPS Act.
The speech broke the previous record held by former President Bill Clinton. In 2000, Clinton delivered a speech to a joint session of Congress for one hour and 28 minutes. 
While the length of the speech set records for Trump, it failed to break any viewership records.
An average of 36.6 million viewers tuned into Trump's speech Tuesday according to Nielsen data, reported by <a href="https://variety.com/2025/tv/news/trump-congress-speech-ratings-viewers-1236328626/">Variety</a>.
This marked a 13% increase from former President Joe Biden&#8216;s 2024 State of the Union speech. Biden drew an average of 32.2 million viewers.
While Trump's speech wasn't an official State of the Union speech given his short time in the White House, the viewership lagged previous Trump speeches to Congress.
During his first term, Trump topped that figure in each of his annual State of the Union speeches to Congress. See below:
<ul>
<li>2017: 47.7 million</li>
<li>2018: 45.6 million</li>
<li>2019: 46.8 million</li>
<li>2020: 37.2 million</li>
</ul>
Viewership figures include the major networks and cable outlets that broadcast Trump's speech, but may not include all of the streaming viewership which could factor into the declines.
Fox News, which is owned by Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) said it led the way in Tuesday viewership with an average of 10.7 million viewers during Trump's speech according to the report.
Nielsen also tracked the age of viewers, with an older audience tuning into the broadcast and cable networks to view Trump's speech as seen below:
<ul>
<li>18-34: 5.7% of viewers</li>
<li>35-54: 20.5% of viewers</li>
<li>55 or older: 70.7% of viewers</li>
</ul>
Here are the viewership figures for Biden's past State of the Union speeches:
<ul>
<li>2021: 26.9 million</li>
<li>2022: 38.2 million</li>
<li>2023: 27.3 million</li>
<li>2024: 32.2 million</li>
</ul>
Read Also:<a href="https://www.benzinga.com/25/02/43847433/trump-approval-rating-declines-in-february-unpopular-domestic-and-foreign-policy-ideas"> Trump Approval Rating Declines In February: &#8216;Unpopular Domestic And Foreign Policy Ideas&#8217;</a>
Why It's Important: With the media landscape shifting to streaming and other non-traditional viewership methods, it could be tough to compare the viewership from Tuesday's speech to past presidential speeches.
The same could likely be said for Trump's inauguration on Jan. 20. An average of 24.59 million viewers <a href="https://www.benzinga.com/general/entertainment/25/01/43139381/how-many-people-watched-donald-trumps-2025-inauguration-spoiler-less-than-biden-four-years-ago">watched Trump's inauguration</a>, which was down from 33.76 million who tuned into Biden's first inauguration in 2017 (30.64 million).
Fox News, which is Republican-leaning, also led the way in viewership for Trump's inauguration.
The 2024 election cycle saw many broadcast and cable news outlets see a boost in viewership and advertising revenue with viewers tuning in for coverage.
With Trump now in office, viewership figures appear to have dropped and less people may be willing to tune in to hear him speak while in office this time around.
When it comes to companies benefitting from Trump in office again, Fox News is likely the winner.
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent030625">Lawmakers Are Making Huge Investments In 2025. See What They&#8217;re Buying And Selling With Our Easy-to-Use Tool</a></li>
</ul>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent030625"><img loading="lazy" decoding="async" width="1024" height="330" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06102403/Picture1-1-1024x330.png" alt="When it comes to Donald Trump presidential speeches and television events, Fox News may be the biggest winner." class="wp-image-812455" style="width:920px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06102403/Picture1-1-1024x330.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06102403/Picture1-1-300x97.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06102403/Picture1-1-768x248.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06102403/Picture1-1.png 1430w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Image: Shutterstock

Entertainment

Politics

FOXA

Trump Congressional Speech Comes Up Short In Viewership: Here's How Many People Watched

JP Morgan analyst Melissa Wedel maintains LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Overweight and raises the price target from $65 to $68.

TREE

JP Morgan Maintains Overweight on LendingTree, Raises Price Target to $68

Stifel analyst Brad Reback maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $425 to $340.

Stifel Maintains Buy on MongoDB, Lowers Price Target to $340

Shield AI, the deep-tech company building state-of-the-art autonomy software products and defense aircraft, today announced it has completed a $240 million, F-1 strategic funding round, raising the company's valuation to $5.3 billion.
The financing was completed with major participation from strategic investors L3Harris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) and Hanwha Aerospace (KRX: 012450), as well as participation from existing investors including Andreessen Horowitz, U.S. Innovative Technology, and Washington Harbour. The funds will enable Shield AI to expand the deployment of Hivemind Enterprise to OEMs, governments, and companies to empower the larger robotics and drone industrial base to build autonomy products.

Shield AI Raises $240M At $5.3B Valuation To Scale Hivemind Enterprise, An AI-Powered Autonomy Developer Platform; Financing Was Completed With Major Participation From Strategic Investors L3Harris And Hanwha Aerospace

AGM Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) shares are trading higher on Thursday after the company announced it completed a $5.4 million <a href="https://www.benzinga.com//node/44133287">public offering</a>.
The Details: AGM intends to use the net proceeds in order to buy 2,000 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining machines for a total purchase price of $9.62 million.
The company sold 16.39 million Class A ordinary shares with warrants at a combined price of 33 cents each.
AGM shares are trading with higher-than-normal session volume at 382.53 million shares. The company&#8217;s average session volume over the past 100 days is 1.18 million shares.
Related Link: <a href="https://www.benzinga.com/news/25/03/44166467/shaquille-oneal-one-of-the-wealthiest-americans-a-cookbook-author-and-the-king-of-franchises-admits-i-dont-l">Shaquille O&#8217;Neal, One Of The Wealthiest Americans, A Cookbook Author And &#8216;The King Of Franchises,&#8217; Admits &#8216;I Don&#8217;t Like Rich People Food&#8217;</a>
AGMH Price Action: At the time of writing, AGM shares are trading 122% higher at 22 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

$BTC

AGMH

What's Going On With AGM Group Shares Thursday?

IHRT

iHeartMedia shares are trading higher after the company disclosed that its Ceo Robert Pittman bought 200K shares of its common stock on March 4th.

Truist Securities analyst Tore Svanberg maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $130 to $115.

Truist Securities Maintains Buy on Marvell Tech, Lowers Price Target to $115

JP Morgan analyst Andrea Teixeira maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Underweight and raises the price target from $34 to $36.

Comments

Blue Bird

Blue Bird (BLBD) 옵션

Blue Bird (NASDAQ:BLBD) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌